Candidate Compounds Covid19

(Unterschied zwischen Versionen)

Wechseln zu: Navigation, Suche

Version vom 23. Juni 2020, 14:03 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

current items will be put into the subsections.

other single compounds
Retargeted single compounds
Hydroxychloroquine
Target ACE2, Spike protein
Target TMPRSS2, Spike protein any other covid targed herein
other antiviral compounds
AV Remdesivir
AV Lopinavir
AV Ivermectin

Immunodeviation e.g. by adjuvants or other vaccinations
Radiation therapy
Phototherapy
Active vaccine

007

32496248 2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.
32496246 2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.

32476308 2020. Empirical Treatment and Prevention of COVID-19.
32466136 2020. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.

32486229 2020. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.
32481690 2020. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.
32471278 2020. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.
32471272 2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?

32443911 2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.
32429572 2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.
32429099 2020. Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19.
32408699 2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.
32392184 2020. Clinical trials for COVID-19 should include sex as a variable.

32457038 2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.

32423974 2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?

32475104 2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.
32293020 2020. Palliativ farmakologisk behandling vid svar covid-19.
32444382 2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
32442946 2020. inverted question markBCG versus COVID-19?

32162896 2020. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.

32455942 2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.

32408547 2020. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
32486364 2020. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.

32486488 2020. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.

32418757 2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?

32423024 2020. The Rationale for Potential Pharmacotherapy of COVID-19.
32434254 2020. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.

32505040 2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.

32381590 2020. Ethics of controlled human infection to address COVID-19.

32472939 2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.

32395792 2020. COVID-19: Main therapeutic options.
32507409 2020. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.

32486283 2020. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.
32397643 2020. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.

32485102 2020. Current Perspective of Antiviral Strategies against COVID-19.
32369098 2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).
32398377 2020. Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19.

32462848 2020. Interleukine-1 et blocage du COVID-19.
32495979 2020. Emergence of novel coronavirus and progress toward treatment and vaccine.

32500793 2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.

32433189 2020. Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.

32473596 2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

32391659 2020. [Pharmaceutical care for severe and critically ill patients with COVID-19].

32057209 2020. [Pharmacotherapeutics for the New Coronavirus Pneumonia].
32397700 2020. [Analysis of application of herd immunity as a control strategy for COVID-19].

32473600 2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
32491981 2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.
32487283 2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.
32490731 2020. Targeting SARS-CoV-2 Receptors as a Means for Reducing Infectivity and Improving Antiviral and Immune Response: An Algorithm-based Method For Overcoming Resistance To Antiviral Agents.

32403995 2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.
32499303 2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
32496239 2020. Potential pharmacological agents for COVID-19.

32496237 2020. AYUSH for COVID-19: Science or Superstition?
32454489 2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.
32392562 2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.

32510105 2020. COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics.

32505909 2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.

32492560 2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?
32460209 2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.

32454510 2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.

32487990 2020. Modeling mitigation of influenza epidemics by baloxavir.

32442323 2020. Curcumin as a potential treatment for COVID-19.
32430996 2020. Potential effects of curcumin in the treatment of COVID-19 infection.

32503877 2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.

32492211 2020. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.

32492205 2020. COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.

32421836 2020. Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients.

32427774 2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.
32427277 2020. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.
32495940 2020. Probiotics and COVID-19: is there any link?
32504751 2020. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.
32505910 2020. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1beta/neutrophil extracellular traps feedback loop.
32502901 2020. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.

32505070 2020. Nebulized Lidocaine in COVID-19, An Hypothesis.

32369285 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369284 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369283 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369282 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369281 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32438383 2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.
32325475 2020. The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.

32393915 2020. Biggest COVID-19 trial tests repurposed drugs first.
32417850 2020. Drug researchers pursue new lines of attack against COVID-19.
32415300 2020. Biotech companies prepare for COVID-19 downturn.
32415251 2020. 15 drugs being tested to treat COVID-19 and how they would work.

32422645 2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.
32415276 2020. The sprint to solve coronavirus protein structures - and disarm them with drugs.
32409766 2020. Dozens of coronavirus drugs are in development - what happens next?
32405023 2020. Coronavirus drugs trials must get bigger and more collaborative.

32512579 2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.
32504019 2020. The coronavirus outbreak could make it quicker and easier to trial drugs.
32424192 2020. CRISPR tool scales up to interrogate a huge line-up of viral suspects.

32324361 2020. [Farmakoterapias lehetosegek SARS-CoV-2-fertozes/COVID-19-betegseg eseten]

32398330 2020. A Call for Pediatric COVID-19 Clinical Trials.
32423342 2020. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?
32393419 2020. Recent advances of therapeutic targets and potential drugs of COVID-19.

32472655 2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.
32501634 2020. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?
32488956 2020. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?

32439730 2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?

32116200 2020. COVID-19: Perspectives on the Potential Novel Global Threat.

32385052 2020. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
32381697 2020. The race is on for antibodies that stop the new coronavirus.
32381692 2020. Combination prevention for COVID-19.
32461212 2020. Reducing transmission of SARS-CoV-2.
32385101 2020. Rapid repurposing of drugs for COVID-19.
32327575 2020. NIH organizes hunt for drugs.

32409433 2020. Antivirals for COVID-19.

32420637 2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.
32294756 2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.

32438473 2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.

32512271 2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.

32448098 2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.

32448085 2020. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.

32431217 2020. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity.

32469418 2020. Evaluation of potential therapeutic options for COVID-19.

32441805 2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.
32437001 2020. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope".

32472779 2020. Food protein-derived antihypertensive peptides in the COVID-19 pandemic: friends of foes?
32508069 2020. Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19.
32470199 2020. Metformin use amid coronavirus disease 2019 pandemic.

32458502 2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.
32458475 2020. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic.

32458425 2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.

32437019 2020. Baricitinib: A chance to treat COVID-19?

32463459 2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.

32428941 2020. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.
32498081 2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

32449669 2020. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.

32495917 2020. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.

32427004 2020. Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?
32452701 2020. An up-to-date overview of computational polypharmacology in modern drug discovery.

32447996 2020. Treatments in the COVID-19 pandemic: an update on clinical trials.
32475183 2020. Does lopinavir measure up in the treatment of COVID-19?

32282262 2020. Treatment considerations for coronavirus (COVID-19).
32469280 2020. COVID-19: Gene Transfer to the Rescue?
32423245 2020. The Impact of the COVID-19 Pandemic on the Biotech Industry.
32212981 2020. A Message to Our Community in the Midst of the COVID-19 Pandemic.
32501133 2020. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?
32503817 2020. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
32503816 2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.

32503814 2020. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
32449676 2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.
32468014 2020. Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).

32310670 2020. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis.

32443151 2020. Lopinavir pharmacokinetics in COVID-19 patients.
32462858 2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.
32469279 2020. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.

32462988 2020. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem).

32475223 2020. Antiviral effects of probiotic metabolites on COVID-19.
32462970 2020. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.

32462996 2020. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment.

32476574 2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms.
32485061 2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.

32433345 2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2.

32473011 2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.
32504739 2020. Interleukin-17: A potential therapeutic target in COVID-19.
32473010 2020. TPE-nAbs combination therapy for severe COVID-19.
32220033 2020. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).

32511912 2020. COVID-19: Drug targets and potential treatments.
32469301 2020. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.

32472703 2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.
32427773 2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.
32364561 2020. Randomized Clinical Trials and COVID-19: Managing Expectations.
32463427 2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic.
32453363 2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19.

32506195 2020. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.

32463794 2020. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.

32434272 2020. COVID-19Clinical trials: quality matters more than quantity.

32464736 2020. A simulation training course for family medicine residents in China managing COVID-19.
32505821 2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.

32455629 2020. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.

32398343 2020. Should azithromycin be used to treat COVID-19? A rapid review.

32454500 2020. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.
32453693 2020. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".
32453692 2020. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.

32267762 2020. Research towards treating COVID-19.

32433778 2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
32442317 2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).
32441783 2020. A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).
32441764 2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?
32424836 2020. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.
32449802 2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?
32512007 2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.
32445484 2020. A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.
32438446 2020. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
32508009 2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.
32441462 2020. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.
32511867 2020. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials.
32418327 2020. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.

32449939 2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.

32420947 2020. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).
32420936 2020. Treatments for COVID-19: emerging drugs against the coronavirus.
32425152 2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
32506621 2020. Drugs being investigated for children with COVID-19.

32423954 2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.

32493028 2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.

32510142 2020. alpha-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.
32407491 2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.

32403134 2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.
32345591 2020. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials.
32303505 2020. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.
32407551 2020. Interrogation of the safety and efficacy of home-use light-based devices.

32480418 2020. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID-19 patients.

32498751 2020. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps.

32429705 2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.
32412788 2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.
32503806 2020. The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.
32474583 2020. In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses.
32459003 2020. A role for retinoids in the treatment of COVID-19?

32459832 2020. Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.
32442287 2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.

32498131 2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic.

32350861 2020. COVID-19: A Defining Moment for Clinical Pharmacology?
32442315 2020. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.

32212378 2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.

32284037 2020. Perspective on the COVID-19 Coronavirus Outbreak.
32174284 2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19.
32400323 2020. In vitro data of current therapies for SARS-CoV-2.
32427000 2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.

32416679 2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
32394841 2020. COVID-19: An Update on Clinical Trials.
32282303 2020. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.
32475041 2020. Potential role of Anti-IL-17 in COVID-19 treatment.
32473070 2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
32510814 2020. Omalizumab and COVID19 Treatment: Could It Help?
32510734 2020. Azithromycin and COVID-19Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration.
32510719 2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.
32500633 2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.
32419517 2020. Emerging therapies for COVID-19 pneumonia.
32429703 2020. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
32419524 2020. Old and re-purposed drugs for the treatment of COVID-19.
32223349 2020. How could artificial intelligence aid in the fight against coronavirus?

32500928 2020. COVID-19 breakthroughs: separating fact from fiction.

32419212 2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?

32401673 2020. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.

32428965 2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.
32479158 2020. Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?
32464083 2020. P-selectin blockade in COVID-19-related ARDS.
32437628 2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?

32446312 2020. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.
32503855 2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.

32340978 2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al. -rest-
32229705 2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections
32276453 2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
32325124 ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals
32312129 2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic
32336674 ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research
32356251 ä. Medical Toxicology and COVID-19: Our Role in a Pandemic
32243778 2020. Ensuring global access to COVID-19 vaccines
32247324 2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings
32272857 2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks
C7190525 2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
32129977 2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases
29115746 2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies
29717819 2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens
C7194243 ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion
32383008 ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic
32380052 2020. Granulocyte-targeted therapies for airway diseases
32452420 2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro

Candidate Compounds Covid19

Version vom 23. Juni 2020, 14:03 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

007

Meine Werkzeuge

Namensräume

Varianten

Ansichten

Aktionen

Suche

Navigation

Werkzeuge

@@ Zeile 77: / Zeile 77: @@
-{{tp|p=32468742|t=2020. Reply: Vitamin C as a Possible Therapy for COVID-19.|pdf=|usr=007}}
-{{tp|p=32410417|t=2020. Vitamin C as a Possible Therapy for COVID-19.|pdf=|usr=007}}
 {{tp|p=32476308|t=2020. Empirical Treatment and Prevention of COVID-19.|pdf=|usr=007}}
 {{tp|p=32466136|t=2020. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.|pdf=|usr=007}}
-{{tp|p=32455961|t=2020. Potential Application of Whole Body Vibration Exercise For Improving The Clinical Conditions of COVID-19 Infected Individuals: A Narrative Review From the World Association of Vibration Exercise Experts (WAVex) Panel.|pdf=|usr=007}}
 {{tp|p=32486229|t=2020. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.|pdf=|usr=007}}
 {{tp|p=32481690|t=2020. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.|pdf=|usr=007}}
@@ Zeile 93: / Zeile 91: @@
 {{tp|p=32408699|t=2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.|pdf=|usr=007}}
 {{tp|p=32392184|t=2020. Clinical trials for COVID-19 should include sex as a variable.|pdf=|usr=007}}
-{{tp|p=32456123|t=2020. Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.|pdf=|usr=007}}
 {{tp|p=32457038|t=2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.|pdf=|usr=007}}
@@ Zeile 99: / Zeile 97: @@
 {{tp|p=32423974|t=2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?|pdf=|usr=007}}
-{{tp|p=32475851|t=2020. COVID-19: Stay Cool toward Corticosteroids.|pdf=|usr=007}}
 {{tp|p=32475104|t=2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.|pdf=|usr=007}}
 {{tp|p=32293020|t=2020. Palliativ farmakologisk behandling vid svar covid-19.|pdf=|usr=007}}
@@ Zeile 108: / Zeile 106: @@
 {{tp|p=32162896|t=2020. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.|pdf=|usr=007}}
-{{tp|p=32407051|t=2020. Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19?|pdf=|usr=007}}
 {{tp|p=32455942|t=2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.|pdf=|usr=007}}
@@ Zeile 115: / Zeile 113: @@
 {{tp|p=32486364|t=2020. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.|pdf=|usr=007}}
-{{tp|p=32397511|t=2020. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2.|pdf=|usr=007}}
 {{tp|p=32486488|t=2020. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.|pdf=|usr=007}}
-{{tp|p=32471251|t=2020. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis.|pdf=|usr=007}}
-{{tp|p=32438620|t=2020. COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation.|pdf=|usr=007}}
-{{tp|p=32492809|t=2020. Vitamin D Supplementation in Influenza and COVID-19 Infections Comment on: "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths" Nutrients 2020, 12(4), 988.|pdf=|usr=007}}
-{{tp|p=32492787|t=2020. Reply: "Vitamin D Supplementation in Influenza and COVID-19 Infections. Comment on: Evidence That Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths Nutrients 2020, 12(4), 988".|pdf=|usr=007}}
 {{tp|p=32418757|t=2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?|pdf=|usr=007}}
-{{tp|p=32471171|t=2020. Excess Ascorbate is a Chemical Stress Agent against Proteins and Cells.|pdf=|usr=007}}
 {{tp|p=32423024|t=2020. The Rationale for Potential Pharmacotherapy of COVID-19.|pdf=|usr=007}}
 {{tp|p=32434254|t=2020. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.|pdf=|usr=007}}
-{{tp|p=32470046|t=2020. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light.|pdf=|usr=007}}
 {{tp|p=32505040|t=2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.|pdf=|usr=007}}
-{{tp|p=32491112|t=2020. Does Vitamin D play a role in the management of Covid-19 in Brazil?|pdf=|usr=007}}
 {{tp|p=32381590|t=2020. Ethics of controlled human infection to address COVID-19.|pdf=|usr=007}}
-{{tp|p=32472653|t=2020. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.|pdf=|usr=007}}
 {{tp|p=32472939|t=2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.|pdf=|usr=007}}
-{{tp|p=32447783|t=2020. Convalescent plasma for COVID-19: Back to the future.|pdf=|usr=007}}
-{{tp|p=32449169|t=2020. How did we rapidly implement a convalescent plasma program?|pdf=|usr=007}}
-{{tp|p=32449171|t=2020. COVID-19: are neutralizing antibodies neutralizing enough?|pdf=|usr=007}}
-{{tp|p=32428966|t=2020. COVID-19 convalescent plasma donor recruitment: beware the Faustian bargains.|pdf=|usr=007}}
 {{tp|p=32395792|t=2020. COVID-19: Main therapeutic options.|pdf=|usr=007}}
 {{tp|p=32507409|t=2020. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.|pdf=|usr=007}}
@@ Zeile 144: / Zeile 136: @@
 {{tp|p=32486283|t=2020. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.|pdf=|usr=007}}
 {{tp|p=32397643|t=2020. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.|pdf=|usr=007}}
-{{tp|p=32464700|t=2020. Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety.|pdf=|usr=007}}
 {{tp|p=32485102|t=2020. Current Perspective of Antiviral Strategies against COVID-19.|pdf=|usr=007}}
 {{tp|p=32369098|t=2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).|pdf=|usr=007}}
-{{tp|p=32398379|t=2020. Convalescent plasma for patients with COVID-19.|pdf=|usr=007}}
-{{tp|p=32398378|t=2020. Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19.|pdf=|usr=007}}
 {{tp|p=32398377|t=2020. Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19.|pdf=|usr=007}}
-{{tp|p=32438839|t=2020. Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?|pdf=|usr=007}}
 {{tp|p=32462848|t=2020. Interleukine-1 et blocage du COVID-19.|pdf=|usr=007}}
 {{tp|p=32495979|t=2020. Emergence of novel coronavirus and progress toward treatment and vaccine.|pdf=|usr=007}}
-{{tp|p=32512588|t=2020. Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19.|pdf=|usr=007}}
-{{tp|p=32453251|t=2020. Extracorporeal Hemoadsorption: An Option for COVID-19 Associated Cytokine Storm Syndrome.|pdf=|usr=007}}
-{{tp|p=32496422|t=2020. Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis.|pdf=|usr=007}}
 {{tp|p=32500793|t=2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.|pdf=|usr=007}}
-{{tp|p=32380908|t=2020. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.|pdf=|usr=007}}
 {{tp|p=32433189|t=2020. Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.|pdf=|usr=007}}
 {{tp|p=32473596|t=2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.|pdf=|usr=007}}
-{{tp|p=32491199|t=2020. Feasibility of a Pilot Program for COVID-19 Convalescent Plasma Collection in Wuhan, China.|pdf=|usr=007}}
@@ Zeile 167: / Zeile 157: @@
 {{tp|p=32391659|t=2020. [Pharmaceutical care for severe and critically ill patients with COVID-19].|pdf=|usr=007}}
-{{tp|p=32489024|t=2020. [Discovery of intervention effect of Chinese herbal formulas on COVID-19 pulmonary fibrosis treated by VEGFR and FGFR inhibitors].|pdf=|usr=007}}
-{{tp|p=32450629|t=2020. [Application of convalescent plasma therapy on novel coronavirus infection].|pdf=|usr=007}}
-{{tp|p=32034899|t=2020. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].|pdf=|usr=007}}
@@ Zeile 192: / Zeile 182: @@
 {{tp|p=32510105|t=2020. COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics.|pdf=|usr=007}}
-{{tp|p=32462719|t=2020. Nutrition Therapy in Critically Ill Patients with Coronavirus Disease (COVID-19).|pdf=|usr=007}}
 {{tp|p=32505909|t=2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.|pdf=|usr=007}}
-{{tp|p=32512490|t=2020. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19.|pdf=|usr=007}}
 {{tp|p=32492560|t=2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?|pdf=|usr=007}}
 {{tp|p=32460209|t=2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.|pdf=|usr=007}}
-{{tp|p=32512493|t=2020. The effects of allium sativum on immunity within the scope of COVID-19 infection.|pdf=|usr=007}}
 {{tp|p=32454510|t=2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.|pdf=|usr=007}}
-{{tp|p=32492996|t=2020. Management of nutritional consultations in local clinics during SARS-CoV-2 pandemic.|pdf=|usr=007}}
 {{tp|p=32487990|t=2020. Modeling mitigation of influenza epidemics by baloxavir.|pdf=|usr=007}}
-{{tp|p=32506067|t=2020. Covid-19 and Exercise-Induced Immunomodulation.|pdf=|usr=007}}
-{{tp|p=32468635|t=2020. Food as medicine: a possible preventive measure against coronavirus disease (COVID-19).|pdf=|usr=007}}
 {{tp|p=32442323|t=2020. Curcumin as a potential treatment for COVID-19.|pdf=|usr=007}}
 {{tp|p=32430996|t=2020. Potential effects of curcumin in the treatment of COVID-19 infection.|pdf=|usr=007}}
-{{tp|p=32424845|t=2020. Artemisia annua: Trials are needed for COVID-19.|pdf=|usr=007}}
 {{tp|p=32503877|t=2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.|pdf=|usr=007}}
@@ Zeile 217: / Zeile 207: @@
 {{tp|p=32421836|t=2020. Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients.|pdf=|usr=007}}
-{{tp|p=32506862|t=2020. Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients.|pdf=|usr=007}}
 {{tp|p=32427774|t=2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.|pdf=|usr=007}}
 {{tp|p=32427277|t=2020. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.|pdf=|usr=007}}
@@ Zeile 251: / Zeile 241: @@
 {{tp|p=32424192|t=2020. CRISPR tool scales up to interrogate a huge line-up of viral suspects.|pdf=|usr=007}}
-{{tp|p=32299148|t=2020. Considerations for Obesity, Vitamin D, and Physical Activity Amid the COVID-19 Pandemic.|pdf=|usr=007}}
 {{tp|p=32324361|t=2020. [Farmakoterapias lehetosegek SARS-CoV-2-fertozes/COVID-19-betegseg eseten]|pdf=|usr=007}}
@@ Zeile 258: / Zeile 248: @@
 {{tp|p=32423342|t=2020. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?|pdf=|usr=007}}
 {{tp|p=32393419|t=2020. Recent advances of therapeutic targets and potential drugs of COVID-19.|pdf=|usr=007}}
-{{tp|p=32476189|t=2020. SARS-CoV-2 pandemic and Vitamin D deficiency-A double trouble.|pdf=|usr=007}}
 {{tp|p=32472655|t=2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.|pdf=|usr=007}}
 {{tp|p=32501634|t=2020. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?|pdf=|usr=007}}
@@ Zeile 266: / Zeile 256: @@
 {{tp|p=32116200|t=2020. COVID-19: Perspectives on the Potential Novel Global Threat.|pdf=|usr=007}}
-{{tp|p=32472681|t=2020. Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease.|pdf=|usr=007}}
 {{tp|p=32385052|t=2020. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.|pdf=|usr=007}}
 {{tp|p=32381697|t=2020. The race is on for antibodies that stop the new coronavirus.|pdf=|usr=007}}
 {{tp|p=32381692|t=2020. Combination prevention for COVID-19.|pdf=|usr=007}}
-{{tp|p=32393526|t=2020. A strategic approach to COVID-19 vaccine R&D.|pdf=|usr=007}}
-{{tp|p=32385100|t=2020. Rapid COVID-19 vaccine development.|pdf=|usr=007}}
 {{tp|p=32461212|t=2020. Reducing transmission of SARS-CoV-2.|pdf=|usr=007}}
 {{tp|p=32385101|t=2020. Rapid repurposing of drugs for COVID-19.|pdf=|usr=007}}
@@ Zeile 279: / Zeile 267: @@
 {{tp|p=32409433|t=2020. Antivirals for COVID-19.|pdf=|usr=007}}
-{{tp|p=32456767|t=2020. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?|pdf=|usr=007}}
-{{tp|p=32490931|t=2020. 17beta-Estradiol, a potential ally to alleviate SARS-CoV-2 infection.|pdf=|usr=007}}
-{{tp|p=32444482|t=2020. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.|pdf=|usr=007}}
-{{tp|p=32409522|t=2020. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.|pdf=|usr=007}}
 {{tp|p=32420637|t=2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.|pdf=|usr=007}}
 {{tp|p=32294756|t=2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.|pdf=|usr=007}}
 {{tp|p=32438473|t=2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.|pdf=|usr=007}}
-{{tp|p=32496938|t=2020. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.|pdf=|usr=007}}
 {{tp|p=32512271|t=2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.|pdf=|usr=007}}
-{{tp|p=32512383|t=2020. Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy.|pdf=|usr=007}}
 {{tp|p=32448098|t=2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.|pdf=|usr=007}}
@@ Zeile 301: / Zeile 289: @@
 {{tp|p=32469418|t=2020. Evaluation of potential therapeutic options for COVID-19.|pdf=|usr=007}}
-{{tp|p=32445400|t=2020. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?|pdf=|usr=007}}
 {{tp|p=32441805|t=2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.|pdf=|usr=007}}
 {{tp|p=32437001|t=2020. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope".|pdf=|usr=007}}
@@ Zeile 308: / Zeile 296: @@
 {{tp|p=32508069|t=2020. Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19.|pdf=|usr=007}}
 {{tp|p=32470199|t=2020. Metformin use amid coronavirus disease 2019 pandemic.|pdf=|usr=007}}
-{{tp|p=32470160|t=2020. Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient.|pdf=|usr=007}}
 {{tp|p=32458502|t=2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.|pdf=|usr=007}}
 {{tp|p=32458475|t=2020. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic.|pdf=|usr=007}}
 {{tp|p=32458425|t=2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.|pdf=|usr=007}}
-{{tp|p=32441786|t=2020. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.|pdf=|usr=007}}
-{{tp|p=32437024|t=2020. Convalescent plasma therapy: A passive therapy for an aggressive COVID-19.|pdf=|usr=007}}
 {{tp|p=32437019|t=2020. Baricitinib: A chance to treat COVID-19?|pdf=|usr=007}}
-{{tp|p=32437014|t=2020. A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19.|pdf=|usr=007}}
 {{tp|p=32463459|t=2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.|pdf=|usr=007}}
-{{tp|p=32492084|t=2020. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.|pdf=|usr=007}}
 {{tp|p=32428941|t=2020. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.|pdf=|usr=007}}
 {{tp|p=32498081|t=2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).|pdf=|usr=007}}
@@ Zeile 348: / Zeile 336: @@
 {{tp|p=32449676|t=2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.|pdf=|usr=007}}
 {{tp|p=32468014|t=2020. Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).|pdf=|usr=007}}
-{{tp|p=32401694|t=2020. Flying by the seat of our pants: is low dose radiation therapy for COVID-19 an option?|pdf=|usr=007}}
-{{tp|p=32468508|t=2020. Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol.|pdf=|usr=007}}
 {{tp|p=32310670|t=2020. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis.|pdf=|usr=007}}
@@ Zeile 367: / Zeile 355: @@
 {{tp|p=32476574|t=2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms.|pdf=|usr=007}}
 {{tp|p=32485061|t=2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.|pdf=|usr=007}}
-{{tp|p=32487869|t=2020. COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?|pdf=|usr=007}}
 {{tp|p=32433345|t=2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2.|pdf=|usr=007}}
-{{tp|p=32511763|t=2020. Colchicine and COVID-19.|pdf=|usr=007}}
 {{tp|p=32473011|t=2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.|pdf=|usr=007}}
 {{tp|p=32504739|t=2020. Interleukin-17: A potential therapeutic target in COVID-19.|pdf=|usr=007}}
@@ Zeile 383: / Zeile 371: @@
 {{tp|p=32463427|t=2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic.|pdf=|usr=007}}
 {{tp|p=32453363|t=2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19.|pdf=|usr=007}}
-{{tp|p=32492105|t=2020. A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals.|pdf=|usr=007}}
 {{tp|p=32506195|t=2020. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.|pdf=|usr=007}}
 {{tp|p=32463794|t=2020. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.|pdf=|usr=007}}
-{{tp|p=32432810|t=2020. Letter: does vitamin D have a potential role against COVID-19?|pdf=|usr=007}}
 {{tp|p=32434272|t=2020. COVID-19Clinical trials: quality matters more than quantity.|pdf=|usr=007}}
-{{tp|p=32384798|t=2020. Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19.|pdf=|usr=007}}
 {{tp|p=32464736|t=2020. A simulation training course for family medicine residents in China managing COVID-19.|pdf=|usr=007}}
 {{tp|p=32505821|t=2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.|pdf=|usr=007}}
@@ Zeile 397: / Zeile 385: @@
 {{tp|p=32398343|t=2020. Should azithromycin be used to treat COVID-19? A rapid review.|pdf=|usr=007}}
-{{tp|p=32464624|t=2020. Cytokine Blood Filtration Responses in COVID-19.|pdf=|usr=007}}
 {{tp|p=32454500|t=2020. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.|pdf=|usr=007}}
 {{tp|p=32453693|t=2020. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".|pdf=|usr=007}}
 {{tp|p=32453692|t=2020. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.|pdf=|usr=007}}
-{{tp|p=32453687|t=2020. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.|pdf=|usr=007}}
 {{tp|p=32267762|t=2020. Research towards treating COVID-19.|pdf=|usr=007}}
-{{tp|p=32453903|t=2020. Efficacy of therapeutic plasma exchange in severe COVID-19 patients.|pdf=|usr=007}}
-{{tp|p=32438450|t=2020. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.|pdf=|usr=007}}
 {{tp|p=32433778|t=2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.|pdf=|usr=007}}
 {{tp|p=32442317|t=2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).|pdf=|usr=007}}
@@ Zeile 425: / Zeile 413: @@
 {{tp|p=32425152|t=2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.|pdf=|usr=007}}
 {{tp|p=32506621|t=2020. Drugs being investigated for children with COVID-19.|pdf=|usr=007}}
-{{tp|p=32468505|t=2020. Association between low vitamin D and COVID-19: don't forget the vitamin D binding protein.|pdf=|usr=007}}
 {{tp|p=32423954|t=2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.|pdf=|usr=007}}
 {{tp|p=32493028|t=2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.|pdf=|usr=007}}
-{{tp|p=32362105|t=2020. What information can I share with my patients about nutrition during COVID-19?|pdf=|usr=007}}
 {{tp|p=32510142|t=2020. alpha-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.|pdf=|usr=007}}
 {{tp|p=32407491|t=2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.|pdf=|usr=007}}
@@ Zeile 451: / Zeile 439: @@
 {{tp|p=32442287|t=2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.|pdf=|usr=007}}
-{{tp|p=32427279|t=2020. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19.|pdf=|usr=007}}
-{{tp|p=32503801|t=2020. Does vitamin D deficiency increase the severity of COVID-19?|pdf=|usr=007}}
-{{tp|p=32341077|t=2020. Nutritional status and COVID-19: an opportunity for lasting change?|pdf=|usr=007}}
 {{tp|p=32498131|t=2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic.|pdf=|usr=007}}
@@ Zeile 461: / Zeile 449: @@
-{{tp|p=32420691|t=2020. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.|pdf=|usr=007}}
 {{tp|p=32212378|t=2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.|pdf=|usr=007}}
-{{tp|p=32406927|t=2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.|pdf=|usr=007}}
 {{tp|p=32284037|t=2020. Perspective on the COVID-19 Coronavirus Outbreak.|pdf=|usr=007}}
 {{tp|p=32174284|t=2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19.|pdf=|usr=007}}
@@ Zeile 469: / Zeile 457: @@
 {{tp|p=32427000|t=2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.|pdf=|usr=007}}
-{{tp|p=32487877|t=2020. Editorial: Challenges and Insights amidst the Covid-19 pandemic: Nutrition, the immune system and disease risk.|pdf=|usr=007}}
-{{tp|p=32487876|t=2020. Nutrition in times of Covid-19, how to trust the deluge of scientific information.|pdf=|usr=007}}
-{{tp|p=32479246|t=2020. Mesenchymal Stem Cell-based Therapy for COVID-19: Possibility and Potential.|pdf=|usr=007}}
 {{tp|p=32416679|t=2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.|pdf=|usr=007}}
 {{tp|p=32394841|t=2020. COVID-19: An Update on Clinical Trials.|pdf=|usr=007}}
@@ Zeile 485: / Zeile 473: @@
 {{tp|p=32419524|t=2020. Old and re-purposed drugs for the treatment of COVID-19.|pdf=|usr=007}}
 {{tp|p=32223349|t=2020. How could artificial intelligence aid in the fight against coronavirus?|pdf=|usr=007}}
-{{tp|p=32490453|t=2020. Luminescent silicon nanostructures and COVID-19.|pdf=|usr=007}}
 {{tp|p=32500928|t=2020. COVID-19 breakthroughs: separating fact from fiction.|pdf=|usr=007}}
-{{tp|p=32505474|t=2020. Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy.|pdf=|usr=007}}
 {{tp|p=32419212|t=2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?|pdf=|usr=007}}
-{{tp|p=32505362|t=2020. Investigate Oral Zinc as a Prophylactic Treatment for Those at Risk for COVID-19.|pdf=|usr=007}}
 {{tp|p=32401673|t=2020. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.|pdf=|usr=007}}
-{{tp|p=32420751|t=2020. Evaluation of the Adjuvant Efficacy of Natural Herbal Medicine on COVID-19: A Retrospective Matched Case-Control Study.|pdf=|usr=007}}
 {{tp|p=32428965|t=2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.|pdf=|usr=007}}
 {{tp|p=32479158|t=2020. Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?|pdf=|usr=007}}
@@ Zeile 501: / Zeile 489: @@
 {{tp|p=32446312|t=2020. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.|pdf=|usr=007}}
 {{tp|p=32503855|t=2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.|pdf=|usr=007}}
-{{tp|p=32503853|t=2020. COVID-19 infection in a patient with FMF: does colchicine have a protective effect?|pdf=|usr=007}}
 {{tp|p=32340978|t=2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.|pdf=|usr=007}}
 -rest-